Investigational Drug Information for TAK-925
✉ Email this page to a colleague
What is the drug development status for TAK-925?
TAK-925 is an investigational drug.
There have been 8 clinical trials for TAK-925.
The most recent clinical trial was a Phase 1 trial, which was initiated on May 3rd 2023.
The most common disease conditions in clinical trials are Apnea, Sleep Apnea, Obstructive, and Sleep Apnea Syndromes. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and [disabled in preview].
There is one US patent protecting this investigational drug and thirty-nine international patents.
Summary for TAK-925
| US Patents | 1 |
| International Patents | 39 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 4 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2023-05-03) |
| Vendors | 19 |
Recent Clinical Trials for TAK-925
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery | Takeda | Phase 2 |
| A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea | Takeda | Phase 1 |
| A Study of Danavorexton in Anesthetized Adults | Takeda | Phase 1 |
Clinical Trial Summary for TAK-925
Top disease conditions for TAK-925
Top clinical trial sponsors for TAK-925
International Patents for TAK-925
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| TAK-925 | Argentina | AR107519 | 2036-02-04 | ⤷ Sign Up |
| TAK-925 | Australia | AU2017215021 | 2036-02-04 | ⤷ Sign Up |
| TAK-925 | Brazil | BR112018015574 | 2036-02-04 | ⤷ Sign Up |
| TAK-925 | Canada | CA3013428 | 2036-02-04 | ⤷ Sign Up |
| TAK-925 | Chile | CL2018002099 | 2036-02-04 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
